1. Home
  2. HG vs VERA Comparison

HG vs VERA Comparison

Compare HG & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Insurance Group Ltd. Class B

HG

Hamilton Insurance Group Ltd. Class B

N/A

Current Price

$35.01

Market Cap

2.4B

Sector

N/A

ML Signal

N/A

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

N/A

Current Price

$31.10

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HG
VERA
Founded
2013
2016
Country
Bermuda
United States
Employees
N/A
361
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.2B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
HG
VERA
Price
$35.01
$31.10
Analyst Decision
Buy
Strong Buy
Analyst Count
7
15
Target Price
$38.14
★ $74.20
AVG Volume (30 Days)
333.8K
★ 1.6M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 5.81%
N/A
EPS Growth
★ 51.23
N/A
EPS
★ 2.73
N/A
Revenue
★ $2,905,524,000.00
N/A
Revenue This Year
$4.03
N/A
Revenue Next Year
$2.31
$841.44
P/E Ratio
$12.62
★ N/A
Revenue Growth
★ 24.70
N/A
52 Week Low
$22.66
$23.05
52 Week High
$37.31
$56.05

Technical Indicators

Market Signals
Indicator
HG
VERA
Relative Strength Index (RSI) 48.90 53.32
Support Level $33.22 $30.05
Resistance Level $36.86 $36.95
Average True Range (ATR) 0.97 1.59
MACD -0.14 0.43
Stochastic Oscillator 38.35 85.80

Price Performance

Historical Comparison
HG
VERA

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: